In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls

- Effect of b/cDMARDs on fibrocyte differentiation
- Denosumab and biologics in rheumatic diseases
- Ginger extract suppresses the activations of NF-κB
- Know your numbers in patients with RA
- Anti-CD74 and spondyloarthropathies
- Behçet’s syndrome: A single-center cohort
- Biologics in Behçet’s disease
Editorial Board

Julian Ambrus
Division of Allergy, Immunology and Rheumatology, Buffalo School of Medicine, Buffalo, NY, USA

Iannis Adamopoulos
Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis School of Medicine, California, USA

Nurullah Akkoç
Division of Rheumatology and Immunology, Department of Internal Medicine, Dokuz Eylül University School of Medicine, İzmir, Turkey

Sibel Zehra Aydın
Division of Rheumatology, Ottawa University School of Medicine, Ottawa, Canada

Ernest Brah
Department of Rheumatology, UCLA School of Medicine, CA, USA

Dimitrios Boumpas
Department of Internal Medicine and Rheumatology, Clinical Immunology and Allergy, University of Crete, Crete, Greece

Juan Jesus Gomez Reino Carnata
Division of Rheumatology, Department of Medicine, Hospital Clinico Universitario, Choupana, Santiago de Compostela, Spain

David D Cruz
Louise Coote Lupus Unit, St Thomas’ Hospital, London, UK

Hanner Direskeneli
Division of Rheumatology, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey

Paul Emery
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Doruk Erkan
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Eugen Feist
Department of Rheumatology, Cooperation Partner of the Otto-von-Guericke University, Magdeburg, Germany

Cem Gabay
Division of Rheumatology, Geneva University Hospitals, Geneva, Italy

Francesco Del Galdo
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Conchi Castillo Gallego
Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain

Tamer A. Gheita
Department of Rheumatology, Cairo University School of Medicine, Giza, Egypt

Allan Gibofsky
Clinic of Rheumatology, Hospital for Special Surgery, New York, NY, USA

Dennis McGonagle
Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds University, Leeds, UK

Vedat Hamuryudan
Division of Rheumatology, Department of Internal Medicine, Istanbul University School of Medicine, Istanbul, Turkey

Nicholas Manolios
Department of Rheumatology, Westmead Hospital, Sydney, Australia

Hilal Maradit Kremers
Department of Health Sciences Research, College of Medicine, Mayo Clinic, Minnesota, USA

Marco Mattucci-Cerinic
Department of Experimental and Clinical Medicine, Division of Rheumatology, AOUC, University of Florence, Florence, Italy

Pier Luigi Meroni
Department of Rheumatology, University of Milan Clinical Sciences and Community Health, Milan, Italy

Devyani Misra
Division of Gerontology and Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Peter Nash
Physician And Rheumatologist, University Of Queensland School of Medicine, Brisbane, QLD, Australia

Seza Özen
Division of Pediatric Rheumatology, Department of Child Health and Diseases, Hacettepe University School of Medicine, Ankara, Turkey

Antonio Gonzales Martinez Pedroya
Division of Rheumatology, Department of Medicine, Hospital Clinico Universitario, Choupana, Santiago de Compostela, Spain

Claus Rasmussen
Department of Bioscience, Aarhus University, Aarhus, Denmark

Carlo Salvarani
Servizio di Reumatologia, Azienda Ospedaliera Arcispedale S. Maria Nuova, Emilia, Italy

Nancy Ann Shadick
Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Yehuda Shoenfeld
Zabladowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Sekib Sokolovic
Clinic for Heart Diseases and Rheumatism, Clinical Center of University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Isaac Ely Stillman
Department of Pathology and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

John H. Stone
Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Elias Toubi
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel

Konstantinos Tsilios
Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

Panayiotis Vlachoyiannopoulos
National and Kapodistrian University of Athens, Athens, Greece

Alvin Wells
Board-certified Rheumatologist Director, Rheumatology and Immunotherapy Center, Franklin, WI, USA

Hasan Yazıcı
Department of Rheumatology, Istanbul University School of Medicine, Istanbul, Turkey
AIMS AND SCOPE

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The aim of the European Journal of Rheumatology is to cover various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case based reviews, letters to the editor and images in rheumatology. The publication language of the journal is English.

The journal’s target audience includes academicians, practitioners, specialists and students from all disciplines of rheumatology.

European Journal of Rheumatology adheres to the principles outlined by the guidelines of ICMJE, WAME, EASE and COPE.

European Journal of Rheumatology is currently indexed in PubMed Central, Web of Science-Emerging Sources Citation Index, EBSCO and CINAHL.

All published content of the European Journal of Rheumatology is available online at eurjrheumatol.org, free of charge.

Statements or opinions expressed in the manuscripts published in the European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

European Journal of Rheumatology is an open access publication and the journal’s publication model is based on Budapest Open Access Initiative (BOAI) declaration. Journal’s archive is available online, free of charge at eurjrheumatol.org. European Journal of Rheumatology content is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Reprint requests and requests concerning advertising should be addressed to the publisher;

Publisher: AVES
Address: Büyükdere Cad. 105/9 34394 Şişli, Istanbul, Turkey
Phone: +90 212 217 17 00
e-mail: info@avesyayincilik.com
avesyayincilik.com
European Journal of Rheumatology (Eur J Rheumatol) is an international, open access, peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on January, April, July and October.

The journal covers various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology. The publication language of the journal is English.

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

Manuscripts submitted to European Journal of Rheumatology will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports or an equivalent official document will be requested from the authors. For manuscripts concerning experimental research on humans, a statement should be included that shows that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo. For studies carried out on animals, the measures taken to prevent pain and suffering of the animals should be stated clearly. Information on patient consent, the name of the ethics committee, and the ethics committee approval number should also be stated in the Materials and Methods section of the manuscript. It is the authors’ responsibility to carefully protect the patients’ anonymity. For photographs that may reveal the identity of the patients, signed releases of the patient or of their legal representative should be enclosed.

All submissions are screened by a similarity detection software (iThenticate by CrossCheck).

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). The ICMJE recommends that authorship be based on the following 4 criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

European Journal of Rheumatology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through www.eurjrheumatol.org) during the initial submission process in order to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of “gift authorship,” the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding
author should also send a short statement declaring that he/she accepts to undertake all the responsibility for authorship during the submission and review stages of the manuscript.

European Journal of Rheumatology requires and encourages the authors and the individuals involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultative, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors. Cases of a potential conflict of interest of the editors, authors, or reviewers are resolved by the journal’s Editorial Board within the scope of COPE and ICMJE guidelines.

The Editorial Board of the journal handles all appeal and complaint cases within the scope of COPE guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve cases that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

European Journal of Rheumatology requires each submission to be accompanied by a Copyright License Agreement (available for download at www.eurjrheumatol.org). When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial, and criminal liabilities in this regard belong to the author(s). By signing the Copyright License Agreement, authors agree that the article, if accepted for publication by the European Journal of Rheumatology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC-BY-NC).

Statements or opinions expressed in the manuscripts published in European Journal of Rheumatology reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility in regard to the published content rests with the authors.

Preprint
European Journal of Rheumatology does not consider preprint publications as prior publication. In other words, authors are allowed to present and discuss their findings on a non-commercial preprint server before submission to a journal.

Authors must provide the journal with the pre-print server deposit of their article accompanying its DOI during initial submission.

If the article is published in the European Journal of Rheumatology, it is the responsibility of the authors to update the archived preprint and link it to the published version of the article.

MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2019 - http://www.icmje.org/icmje-recommendations.pdf). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behaviour.

Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system, available at www.eurjrheumatol.org. Manuscripts submitted via any other medium will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:
- Copyright Agreement,
- Author Contributions Form, and
- ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors)

during the initial submission. These forms are available for download at www.eurjrheumatol.org.

Preparation of the Manuscript
Title page: A separate title page should be submitted with all submissions and this page should include:
- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name(s), affiliations, and highest academic degree(s) of the author(s),
- Grant information and detailed information on the other sources of support,
- Name, address, telephone (including the mobile phone number) and fax numbers, and email address of the corresponding author,
- Acknowledgement of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: An abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Original Articles should be structured with subheadings (Objective, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.
Keywords: Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).

Main Points: All submissions except letters to the editor and images in rheumatology should be accompanied by 3 to 5 “main points” which should emphasize the most noteworthy results of the study and underline the principle message that is addressed to the reader. This section should be structured as itemized to give a general overview of the article. Since “Main Points” targeting the experts and specialists of the field, each item should be written as plain and straightforward as possible.

Manuscript Types
Original Articles: This is the most important type of article since it provides new information based on original research. The main text of original articles should be structured with Introduction, Methods, Results, and Discussion subheadings. Please check Table 1 for the limitations for Original Articles.

Statistical analysis to support conclusions is usually necessary. Statistical analyses must be conducted in accordance with international statistical reporting standards (Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J 1983; 7: 1489-93). Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Units should be prepared in accordance with the International System of Units (SI).

Review Articles: Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The main text should contain Introduction, Clinical and Research Consequences, and Conclusion sections. Please check Table 1 for the limitations for Review Articles.

Case-based Reviews: Case-based reviews are reports on rare cases or conditions that constitute challenges in diagnosis and treatment, incorporating a mini literature review of a particular area of the field. Please check Table 1 for the limitations for Case-based Reviews.

Letters to the Editor: This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers’ attention, particularly educative cases, may also be submitted in the form of a “Letter to the Editor.” Readers can also present their comments on the published manuscripts in the form of a “Letter to the Editor.” Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The manuscript that is being commented on must be properly cited within this manuscript.

Images in Rheumatology: This type of submissions should present a striking image that may challenge and inform readers and contribute to their education. Please check Table 1 for the limitations for Images in Rheumatology.

Table

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>Word limit</th>
<th>Abstract word limit</th>
<th>Reference limit</th>
<th>Table limit</th>
<th>Figure limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Article</td>
<td>3000</td>
<td>400 (Structured)</td>
<td>35</td>
<td>6</td>
<td>7 or total of 15 images</td>
</tr>
<tr>
<td>Review Article</td>
<td>5000</td>
<td>250</td>
<td>50</td>
<td>6</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Case-based Reviews</td>
<td>2400</td>
<td>200</td>
<td>30</td>
<td>No tables</td>
<td>10 or total of 20 images</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>500</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>No media</td>
</tr>
<tr>
<td>Images in Rheumatology</td>
<td>500</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>4 or total of 8 images</td>
</tr>
</tbody>
</table>
the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition.

When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the product, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: “Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)”

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

References

While citing publications, preference should be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided. Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first six authors should be listed followed by “et al.” In the main text of the manuscript, references should be cited using Arabic numbers in parentheses. The reference styles for different types of publications are presented in the following examples.


Editor(s) as Author: Huizing EH, de Groot JAM, editors. Functional reconstructive nasal surgery. Stuttgart-New York: Thieme; 2003.


REVISIONS

When submitting a revised version of a paper, the author must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal’s webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof.

Editor in Chief: George C. Tsokos
Address: Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
E-mail: editorialoffice@eurjrheumatol.org
Publisher: Ahmet Mesut Onat
### Original Articles

**In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls**

Helene Broch Tenstad, Pernille Just Vinholt, Christian Nielsen, Hanne Lindegaard, Søren Andreas Just

**Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases**

Cosimo Bruni, Cosimo Cigolini, Giulia Tesei, Laura Cometi, Francesca Bartoli, Ginevra Fiori, Francesca Nacci, Silvia Bellando-Randone, Serena Guiducci, Marco Matucci-Cerinic

**Ginger extract suppresses the activations of NF-κB and Wnt pathways and protects inflammatory arthritis**

Burak Öz, Cemal Orhan, Mehmet Tuzcu, Nurhan Şahin, Ibrahim Hanifi Özercan, Pınar Demirel Öner, Süleyman Sendar Koca, Vijaya Juturu, Kazım Şahin

**What do patients with rheumatoid arthritis know about their own biomedical data related to cardiovascular disease risks?**

Tanaka Ngcozana, Kevin Corbett, Ajay Bhatia

**The association of anti-CD74 antibody with spondyloarthropathies**

Seda Çokak, Tahsin Murat Turgay, Orhan Kıcıkşahin, Mustafa Türker Duman, Hülya Çetinkaya, Murat Toruner

**Clinical manifestations of Behçet’s syndrome: A single-center cohort of 777 patients**

Cemal Gürbüz, Demet Yağcılar Kehribar, Metin Özgen

### Literature Reviews

**Biologic treatments in Behçet’s disease**

Fatma Alibaz-Öner, Haner Direskeneli

**Use of Non-TNF biologics for the treatment of neuro-Behçet’s disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab**

Yusuf Karabulut

### Case-based Review

**Central nervous system vasculitis in a patient with axial spondyloarthritis treated with infliximab: A case report and literature review**

Panagiotis Panagopoulos, Glikas Katsiflis

### Letter to the Editor

**Declining in-hospital mortality in vasculitis: A 17-year US national study**

Jasvinder A. Singh, John D. Cleveland
CONTENTS

Images in Rheumatology

Syringomyelia presenting as neuropathic arthropathy of basal and shoulder joint
Ganesh Singh Dharmshaktu

Palmoplantar keratoderma as the preceding cutaneous manifestation of juvenile-onset dermatomyositis
Pratap Kumar Patra, Aqib Zaffar Banday, Robin Bansal, Murugan Sudhakar, Ankur Kumar Jindal